Clinical Trial Update: AFPᶜ³³²T in Advanced HCC [Phase 1]

View source ↗

Summary

Status update on Adaptimmune's AFP-C332T trial for advanced hepatocellular carcinoma, with the Phase 1 study currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• AFP-C332T

Snippet

Sponsor: Adaptimmune | Conditions: Hepatocellular Cancer, AFP Expressing Tumors | Phase 1 | Status: ACTIVE_NOT_RECRUITING